ChromaDex Co. (NASDAQ:CDXC – Get Free Report) saw a significant growth in short interest during the month of June. As of June 15th, there was short interest totalling 1,870,000 shares, a growth of 10.7% from the May 31st total of 1,690,000 shares. Approximately 3.9% of the shares of the stock are sold short. Based on an average daily volume of 323,100 shares, the short-interest ratio is presently 5.8 days.
Analysts Set New Price Targets
Several analysts have weighed in on CDXC shares. HC Wainwright reissued a “buy” rating and issued a $6.00 target price on shares of ChromaDex in a report on Thursday, May 9th. Roth Mkm reissued a “buy” rating and issued a $6.00 target price on shares of ChromaDex in a report on Wednesday, June 12th.
Read Our Latest Report on CDXC
Institutional Trading of ChromaDex
ChromaDex Trading Down 1.6 %
Shares of NASDAQ:CDXC traded down $0.04 on Wednesday, hitting $2.54. The company had a trading volume of 133,145 shares, compared to its average volume of 312,715. ChromaDex has a 52-week low of $1.25 and a 52-week high of $4.65. The business has a 50 day moving average of $3.12 and a 200 day moving average of $2.52. The company has a market cap of $191.87 million, a PE ratio of -50.80 and a beta of 1.87.
ChromaDex (NASDAQ:CDXC – Get Free Report) last issued its quarterly earnings data on Wednesday, May 8th. The company reported ($0.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.03) by $0.02. ChromaDex had a negative return on equity of 12.61% and a negative net margin of 4.24%. The business had revenue of $22.15 million for the quarter, compared to the consensus estimate of $22.35 million. As a group, equities analysts predict that ChromaDex will post -0.02 EPS for the current year.
About ChromaDex
ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.
Further Reading
- Five stocks we like better than ChromaDex
- How to Use High Beta Stocks to Maximize Your Investing Profits
- AbbVie Stock: A Perfect Dip for Investors to Buy
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Forget NVIDIA: Super Micro Computer Stock Leads in Momentum
- What Investors Need to Know About Upcoming IPOs
- GitLab Stock Rebounds: The Inside Story of Its Comeback
Receive News & Ratings for ChromaDex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChromaDex and related companies with MarketBeat.com's FREE daily email newsletter.